According to a new study of company leaders, CEOs tend to approach business risks more prudently when compensated with material pay packages as a larger percentage of overall compensation, instead of a heavy dose of stock options.
From one point of view, this makes little sense: Many (many) executives perform just to the point of making stock prices rise quarter after quarter. After all, would you want to buy options with cheap strike prices only to sell them later for massive profit -- company long-term performance be damned? Due to the greedy nature of many CEOs, this situation seems head-on. The only problem here is that this study refutes that belief.
It concluded that CEOs who are granted large numbers of stock options as a main form of compensation are more likely to make riskier decisions with often negative repercussions on company stock prices. This also makes sense: With more stock options on the table, the risk-taker mentality may come out more for leaders-- who ascend to their positions usually by taking risks in the first place.
The only problem is that most of those risks end in bitter disappointments instead of glowing results. Although stock options are geared toward motivating executives and middle managers to improve a company's future performance, the study's authors argue that that form of compensation is not all that effective in increasing a company's overall results. Moral of the story: liberal stock option granting is a good idea, but just don't overload comp packages with them.
Last updated: February 13, 2012: 11:14 AM
Hot Stocks
DailyFinance Headlines
- Retail Stocks Are for Suckers: Why Their Rally Won't Last
- Suddenly, Amazon Doesn't Love Its Moms Anymore
- How State Taxes Put a Bigger Pinch on the Poor
- 4 Money-Etiquette Questions Answered
- Walmart's New Health Food Push: Is It Too Hard to Swallow?
Benzinga Headlines
- Airlines the Latest to Suffer Euro Crisis Blues
- Internet-Hungry Consumers Force Vodafone to Consider a C&W Offer
- Seven Japanese Stocks Up More Than 10% Year to Date
- Does the 2012 Election Really Matter for the Economy?
- Michigan Consumer Sentiment Index Drops
TheFlyOnTheWall.com Headlines
- Diebold FY11 free cash flow exceeded guidance by more than $10M
- Applied Materials March volatility flat into Q1 and sales outlook
- Rumor: Dendreon active on speculation it canceled a conference presentation
- President Obama to discuss FY2013 budget proposal
- Diebold expects the same quarterly seasonality in FY12 as last years'
BioHealth Investor Headlines
- Can Human Genome Really Double Its Stock Price? (HGSI)
- Alimera Implosion Analysis, What Is Next (ALIM, PSDV)
- Implosion Analysis For Targacept… What Lies Ahead? (TRGT, AZN)
- Rare Analyst Calls With Huge Upside in Vical and VIVUS (VICL, VVUS, BMY)
- Top Biotechs With Upside Ahead of Earnings (GILD, AMLN, ARIA, INCY, JAZZ, DNDN, HGSI, ILMN, AMGN, CELG, BIIB, BMRN, LIFE, REGN, AMLN, CBST, ONXX, THRX, VPHM)
WalletPop Headlines
- Retail Stocks Are for Suckers: Why Their Rally Won't Last
- Suddenly, Amazon Doesn't Love Its Moms Anymore
- How State Taxes Put a Bigger Pinch on the Poor
- 4 Money-Etiquette Questions Answered
- Walmart's New Health Food Push: Is It Too Hard to Swallow?
My Portfolios
Track your stocks here!
Find out why more people track their portfolios on AOL Money & Finance then anywhere else.
BloggingStocks Partners
More from AOL Money & Finance
- Business News
- Stock Screener
- Stock Quotes
- Stock Charts
- Banking
- Identity Theft
- DJIA
- Debt Management
- Loans
- Auto Loan
- Mortgages
- Taxes
- Retirement
- Insurance
- Small Business
- Earnings
- Tech News
- Tax Forms
- Tax Deductions
- Tax Credit
- Tax Audit
- Tax Advice
- Stock Ticker
- Stock Brokers
- Resume Builder
- Pig Flu
- Online Tax Filing
- Madoff
- Investing For Retirement
- Income Tax
- Historical Stock Prices
- GOOG
- ETF Investing
- Deals
- DailyFinance
- Crude Oil Prices
- Credit Score Calculator
- Common Tax Filing Mistakes
- AMT
BioHealth Investor Headlines
- Can Human Genome Really Double Its Stock Price? (HGSI)
- Alimera Implosion Analysis, What Is Next (ALIM, PSDV)
- Implosion Analysis For Targacept… What Lies Ahead? (TRGT, AZN)
- Rare Analyst Calls With Huge Upside in Vical and VIVUS (VICL, VVUS, BMY)
- Top Biotechs With Upside Ahead of Earnings (GILD, AMLN, ARIA, INCY, JAZZ, DNDN, HGSI, ILMN, AMGN, CELG, BIIB, BMRN, LIFE, REGN, AMLN, CBST, ONXX, THRX, VPHM)
Walmart's New Health Food Push: Is It Too Hard to Swallow?
Bonds Are a 'Safe' Investment: A Big Lie Gets Even Bigger

